Stockscreener 앱 받기
0.205
3.25%
0.0113
Tnf Pharmaceuticals Inc 주식(TNFA)의 최신 뉴스
A new trading data show TNF Pharmaceuticals Inc (TNFA) is showing positive returns. - Sete News
TNF Pharmaceuticals Inc Inc. (TNFA) Price Performance: A Guide to Financial Ratios - investchronicle.com
Is TNF Pharmaceuticals Inc (TNFA) worth investing in despite its overvalued state? - uspostnews.com
Gaining Ground: TNF Pharmaceuticals Inc (TNFA) Closes Lower at 0.25, Down -9.00 - DWinneX
Comparing TNF Pharmaceuticals (NASDAQ:TNFA) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
TNF Pharmaceuticals Inc (NASDAQ:TNFA) Is Looking Good Over The Long Term, Dropped Nearly -46.01% Over A Month. – Marketing Sentinel - Marketing Sentinel
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ - GlobeNewswire
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
TNF Pharmaceuticals Inc (TNFA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish - MSN
TNF and Renova Health use AI to identify patients for GLP-1 treatments - Yahoo Finance
TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish By Stocktwits - Investing.com India
TNF Pharmaceuticals uses AI to refine patient selection for trials By Investing.com - Investing.com South Africa
TNF Pharmaceuticals uses AI to refine patient selection for trials - Investing.com
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development - Business Wire
Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com
TNF Pharmaceuticals Inc Inc. (TNFA) Price Performance Over the Years: A Comparative Study - investchronicle.com
Market Recap Check: Sangamo Therapeutics Inc (SGMO)’s Positive Finish at 0.71, Up/Down 2.96 - DWinneX
Gaining Ground: TNF Pharmaceuticals Inc (TNFA) Closes Lower at 0.18, Down -25.44 - DWinneX
Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Benzinga
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025 - The Joplin Globe
Corebridge Financial Inc. Trims Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
TNF Pharmaceuticals, Inc. SEC 10-K Report - TradingView
TNF Pharmaceuticals Inc: Navigating Market Fluctuations with a 0.75M Market Cap - investchronicle.com
TNFA stock touches 52-week low at $0.32 amid market challenges - Investing.com Canada
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Now Is A Good Time To Buy TNF Pharmaceuticals Inc (NASDAQ: TNFA) - Marketing Sentinel
A Key Driver Transforming the TNF Alpha Inhibitors Market in 2025: The Prevalence Of Inflammatory Diseases ... - WhaTech
Contrasting Myriad Genetics (NASDAQ:MYGN) & TNF Pharmaceuticals (NASDAQ:TNFA) - Defense World
TNF Pharmaceuticals faces Nasdaq delisting over price - Investing.com
TNF Pharmaceuticals faces Nasdaq delisting over price By Investing.com - Investing.com India
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent - Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Sarcopenia Market Expected to Experience Major Growth by 2034, - openPR.com
TNF Pharmaceuticals presents isomyosamine data - Yahoo Finance
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia - Joplin Globe
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
TNF Pharmaceuticals Discusses Isomyosamine Progress in Call - TipRanks
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 - BioSpace
Raythera describes new TNF-α modulators - BioWorld Online
RILY’s current quarter earnings: What analysts forecast? - US Post News
LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews
Are T1 Energy Inc (FREY) shares a good deal now? - US Post News
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor - BioSpace
Can This First-Ever Oral TNF Inhibitor Disrupt a $40 Billion Market? Phase 2b Trial Begins - StockTitan
2.71%
자본화:
|
볼륨(24시간):